🍯 Exclusive: Niklas Anzinger Interview

Vitalia: The decentralized city focused on longevity

Welcome, humans. This is Ambrosia Path, where we deliver longevity news like a barista that serves your morning coffee – quick, energizing, and right into your daily routine ☕️

Here’s what we got for you today:

  • Exclusive: Niklas Anzinger Interview

  • Daily Longevity Headlines

  • Longevity Meme of the Day

Niklas Anzinger is on the Ambrosia Path

Ladies and gentleman. We have an exciting guest in the house…

Niklas Anzinger!

For those who don’t know, Niklas is…

  • An entrepreneur & investor, currently living on Roatan, Honduras, in the jurisdiction of Prospera ZEDE

  • A founder and general partner of Infinita VC

  • A co-initiator of Vitalia, building a decentralized city to accelerate longevity technology development

We have 10 big questions for Niklas. Ready? Let’s go.

Ambrosia: #1 – What problem does Vitalia solve?

Niklas: Vitalia solves the problem of institutional sclerosis affecting biotech & healthcare innovation, of excessively expensive (billions of $), long and bureaucratic (10-15 years) approval processes.

Ambrosia: #2 – What’s a Biotech Acceleration Zone and why do we need them?

Niklas: Vitalia started as a pop-up city and brought 500+ scientists, entrepreneurs and biohackers together to work on co-working to solve aging and death and co-living for community and personal development. Vitalia is now building the infrastructure for a permanent community living together and do commercial and scientific development of longevity drugs & treatments.

Ambrosia: #3 – Do you have any interesting stories from Vitalia this year? The guest lineup is stacked with so many amazing people. What’s it like to be amongst it all?

Niklas: We community-sourced 6 blood donors to save a man's life, we fixed water damage that affected the entire main facility, and we built a Dome and a cybernetics lab.

Ambrosia: #4 – Are there plans for a second Vitalia? It seems Vitalia ends on April the 1st (having already been extended!)

Niklas: Vitalia does not end on April 1, we're here permanently (we'll continuously announce a new schedule to give new residents a reason to come visit and live with us). We expect a community of 30-50 people to live here April+ and we aim to grow to 200 people by the end of the year.

There are no concrete plans yet for a pop-up city in different locations, but we do expect to run events in different parts of the world to grow the community and develop relations with governments and industries that are interested in harboring a Vitalia district in the future.

Ambrosia: #5 – What is your take on the longevity industry?

Niklas: Longevity is a relatively young industry, and has many problems - but it is overall on a great trajectory to succeed. The biggest myth in the longevity industry to me is the belief that first, we need to improve public perception, to then be able to get things done. It's the opposite: we need to get things done, to improve public perception and mainstream acceptance. The key problem is speed: we're too slow in bringing new solutions to market, which is why we founded Vitalia.

Ambrosia: #6 – Do you have any predictions about the longevity industry in coming years? What is most exciting to you at the moment (companies, research etc)?

Niklas: I am not a biologist, so I am not qualified to comment on promising areas of research and development. I am currently quite excited about cybernetics - it's an industry currently in the hacker stage and regulatorily constrained from entering the medical space. The Augmentation Lab in Vitalia aims to propel the industry to broader acceptance and medical use. This can open up novel ways to measure and intervene in human biology in impactful ways.

Ambrosia: #7 – What do you do personally to improve your longevity? Do you take any supplements or have any special routine?

Niklas: I am fortunate to have been born with a genetic setup that allows me to stay healthy with little intervention other than regular exercise, not too unhealthy diet, and good sleep.

Ambrosia: #8 – Any exciting news or plans coming up for either Infinita VC or Vitalia?

Niklas: Vitalia announced the schedule for March here, including a big showcase event for investors interested in some of the current 38 companies in Vitalia's startup program here.

Ambrosia: #9 – What do you think of the intersection of Decentralised Science (DeSci) and longevity?

Niklas: DeSci and Longevity are important movements in their own right. My contrarian view is that DeSci is less important for Longevity to succeed than it is often portrayed as. Yes, there are important bottlenecks to be overcome in science funding - but the bigger constraints are regulatory, even with the best science in the world, we won't succeed if we don’t build a 10-100x more efficient drug development pipeline and commercial scaling of life extension products.

Ambrosia: #10 – How can our readers learn more and keep up to date with your progress?

Niklas: The best way to get my personal views and news is my blog and podcast called “Stranded Technologies”. Best connect with me is through a personalized contact request on LinkedIn.

Daily Longevity Headlines

  • Famous podcaster Chris Williamson had Dr. Rhonda Patrick in his podcast to share the most important daily habits for longevity 🎙

  • Scientists found gut damage from chronic viral infections like HIV speeds up aging 👀

  • Vitamin D3/plant compounds were found to reduce inflammation & age-related diseases, potentially extending healthy life 🌱

  • Studies show that Rapamycin, a drug, helps reduce aging effects on heart, skin, and immune health ❤️

  • 103-year-old Jamaican grandma shares her secrets for living longer 👵

Longevity Meme of the Day - Don’t share this with your boss

That’s it for longevity news today folks! Have a fantastic day!

Hot Tip: If this email landed in your promotions folder, move it to primary to make sure you see the next edition!

Disclaimer: This information does not constitute health advice or a recommendation and should not be considered as such